Author:
Nsubuga-Nyombi Tamara,Sensalire Simon,Karamagi Esther,Aloyo Judith,Byabagambi John,Rahimzai Mirwais,Nabitaka Linda Kisaakye,Calnan Jacqueline
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Virology,Molecular Medicine
Reference12 articles.
1. Centers for Disease Control and Prevention. Vital signs: HIV prevention through care and treatment—United States. MMWR Morb Mortal Wkly Rep. 2011;60(47):1618–23.
2. Ng’ambi WF, Tweya H, Speight C, Man-Bourdon C, Hosseinpour M, Phiri S. Determinants of antiretroviral treatment adherence among women accessing PMTCT “Option B+”: a retrospective study at Bwaila Hospital, Malawi. In: IAS conference on HIV pathogenesis, treatment and prevention, 30 June–03 July 2013-Kuala Lumpur, Malaysia.
3. Engell CA, Pham VP, Holzman RS, Aberg JA. Virologic outcome of using tenofovir/emtricitabine to treat hepatitis B in HIV-coinfected patients. ISRN Gastroenterol. 2011; 2011:405390.
4. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34(8):1115–21.
5. Winchester MS. Synergistic vulnerabilities: antiretroviral treatment among women in Uganda. Glob Public Health. 2015;10(7):881–94.
https://doi.org/10.1080/17441692.2015.1007468
.